eligibility_summary
Inclusion: 16–65, KPS>60 or ECOG 0–2, B-ALL beyond CR1/induction failure (MRD‑neg allowed) or residual disease (>0.01% by flow, BCR‑ABL ≥1/10,000, or high‑risk genetics), ANC≥0.5×10^9/L, platelets≥20×10^9/L, CrCl≥30 mL/min, ALT/AST≤5×ULN, bilirubin≤3×ULN, berintuzumab 60–100 days post‑transplant, no active aGvHD. Exclusion: serious organ disease, uncontrolled infection, CNS pre‑Tx, PGF post‑allo‑HSCT, second allo‑Tx.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational study in R/R B-ALL after allo-HSCT comparing post-transplant blinatumomab maintenance (with PTCY or ATG GVHD prophylaxis) vs no blinatumomab. Drugs/interventions and mechanisms: blinatumomab—bispecific T-cell engager (BiTE, antibody construct) that binds CD19 on B cells and CD3 on T cells to trigger T cell–mediated cytotoxicity of CD19+ blasts, dexamethasone premed—glucocorticoid to mitigate cytokine release, post-transplant cyclophosphamide—alkylating agent that eliminates proliferating alloreactive T cells, ATG—polyclonal anti–T-cell immunoglobulin that depletes T cells. Targets/pathways: CD19+ B-cell leukemia, CD3/T-cell activation, alloreactive T cells driving GVHD, and TCR/BCR immune repertoire reconstitution.